Biovest Conducts End of Phase III Review with FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin’s Lymphoma

SOURCE: Biovest International, Inc.

Click to read more ...

Biovest’s Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA

SOURCE: Biovest International, Inc.

Click to read more ...

Drug Addiction Vaccine

SOURCE: NewsChannel5.com (Nashville, TN) (Ivanhoe Newswire)

Click to read more ...

Stellar Biotechnologies to Present at ImVacS 2012 Summit on August 13 - 16, 2012

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

Stellar Biotechnologies to Present at ICAAC 2012 Conference on September 9 - 12, 2012

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study

SOURCE: Biovest International, Inc.

Click to read more ...

INTERIM RESULTS FROM NEOVACS’ PHASE II CLINICAL TRIAL IN CROHN’S DISEASE

SOURCE: Neovacs

Click to read more ...

Biovest to Seek Marketing Approval in the EU for BiovaxID(R) Personalized Lymphoma Cancer Vaccine

SOURCE: Biovest International, Inc.

Click to read more ...

Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada

SOURCE: Biovest International, Inc.

Click to read more ...